SQLite Web: event

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-19T11:16:24.661615+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:c7e7e4aad85535dd","evidence_event_ids":["evt_d9b580af54d0"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/best-high-yield-dividend-stocks-buy-2026-and-beyond","as_of":"2026-04-19T11:16:24.661615+00:00","canonical_url":"https://www.fool.com/investing/2026/04/19/the-best-high-yield-dividend-stocks-to-buy-for-202/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/best-high-yield-dividend-stocks-buy-2026-and-beyond","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_35464a7ae11c913f","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/19/the-best-high-yield-dividend-stocks-to-buy-for-202/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-19T11:46:16.758185+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsAbbVie provides an attractive combination of income, value, and growth.","fetched_title":"The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond | Nasdaq","final_url":"https://www.nasdaq.com/articles/best-high-yield-dividend-stocks-buy-2026-and-beyond","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/best-high-yield-dividend-stocks-buy-2026-and-beyond","source_event_id":"evt_d9b580af54d0","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"b7415ffdf56c22c6","kind":"unusual_volume","published_at":"2026-04-19T10:00:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.62,"dates_mentioned":[],"entities":[{"asset_class":"equity","name":"AbbVie","relevance":"high","symbol":"ABBV","type":"company"},{"asset_class":"equity","name":"Enbridge","relevance":"medium","symbol":"ENB","type":"company"},{"asset_class":"equity","name":"Realty Income","relevance":"medium","symbol":"O","type":"company"},{"asset_class":"index","name":"S&P 500","relevance":"low","symbol":"^GSPC","type":"index"},{"asset_class":"macro","name":"Federal Reserve","relevance":"low","symbol":"","type":"institution"}],"event_type":"other","information_gaps":["Signal type is discovery_unusual_volume_delta, but the provided text contains no volume ratio, baseline volume, or any unusual-volume confirmation for any ticker.","No explicit catalyst tied to unusual trading volume is described; the article\u2019s catalysts are general (dividend/valuation/pipeline) rather than trading-volume-driven.","The article does not state whether any volume move is confirmed by news or is unexplained."],"key_facts":["The article states AbbVie (NYSE: ABBV) has a forward dividend yield of 3.3%.","The article states AbbVie has increased its dividend for 53 consecutive years (including when it was part of Abbott Labs).","The article states AbbVie trades at 14.3 times forward earnings.","The article states the S&P 500 forward P/E average is 20 and the S&P 500 healthcare sector forward P/E average is 17.4 (as cited in the article).","The article attributes AbbVie\u2019s growth momentum to autoimmune disease drugs Rinvoq and Skyrizi.","The article states AbbVie\u2019s pipeline includes multiple promising late-stage programs.","The article discusses broader market context: bond yields have risen and the Fed is described as uncertain about inflation and the job market."],"numeric_claims":[{"label":"AbbVie forward dividend yield","value":"3.3%"},{"label":"AbbVie dividend increase streak","value":"53 consecutive years"},{"label":"AbbVie forward earnings multiple (forward P/E)","value":"14.3x"},{"label":"S&P 500 forward P/E average (as stated)","value":"20"},{"label":"S&P 500 healthcare sector forward P/E average (as stated)","value":"17.4"},{"label":"Rinvoq and Skyrizi mentioned","value":"Yes"}],"primary_claim":"AbbVie (ABBV) is presented as a high-yield dividend stock with a forward dividend yield of 3.3% and 53 consecutive years of dividend increases, supported by valuation and pipeline commentary.","relevance_score":0.25,"sentiment":"positive","source_quality":"high","summary":"The article is a \u201cbest high-yield dividend stocks\u201d list for 2026 and beyond, highlighting AbbVie (ABBV) as a Dividend King and discussing its yield, valuation, and drug pipeline. No unusual trading volume information is provided for any ticker.","topics":["high-yield dividend stocks","Dividend Kings","AbbVie dividend history","forward dividend yield","valuation (forward P/E)","drug pipeline (Rinvoq, Skyrizi)","market context (bond yields, Fed uncertainty)"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsAbbVie provides an attractive combination of income, value, and growth.","tickers":[],"title":"The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond","url":"https://www.fool.com/investing/2026/04/19/the-best-high-yield-dividend-stocks-to-buy-for-202/"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — events

Update row 302229 in events